Novo Nordisk today presented new results from the landmark POSEIDON real-world evidence study at the 94th European Atherosclerosis Society (EAS) Congress in Athens, Greece. The study showed that CV inflammation remains highly prevalent among people with CVD despite current standard-of-care
AHA
According to the American Heart Association (AHA) and the World Health Organization (WHO), the Eastern Mediterranean Region (EMR), which includes most Middle East and North Africa (MENA) countries, is now among the regions with the highest prevalence of cardiovascular diseases (CVDs) globally, with a sharp rise attributed to preventable, lifestyle-related risk factors such











